Limitations of IL-2 and rapamycin in immunotherapy of type 1 diabetes

Diabetes

Volumn 62, Issue 9, 2013, Pages 3120-3131

  Baeyens, Audrey ^a,b,c   Pérol, Louis ^a,b,c   Fourcade, Gwladys ^a,b,c   Cagnard, Nicolas ^d,e   Carpentier, Wassila ^a   Woytschak, Janine ^f   Boyman, Onur ^f,g   Hartemann, Agnès ^a,h   Piaggio, Eliane ^a,b,c  

^a SORBONNE UNIVERSITÉ   (France)

^b CNRS   (France)

^c Unit of Dermatology   (France)

^d INSERM   (France)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f UNIVERSITY OF ZURICH   (Switzerland)

^g UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^h HÔPITAL CHARLES FOIX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; RAPAMYCIN; RECOMBINANT INTERLEUKIN 2; STAT5 PROTEIN; TRANSCRIPTION FACTOR FOXP3; INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; BRAIN EDEMA; CELL DIVISION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FEMALE; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; IMMUNOMODULATION; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULITIS; INTERFERON GAMMA RELEASE ASSAY; LIVER METABOLISM; LOW DRUG DOSE; LUNG EDEMA; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SEX DIFFERENCE; T LYMPHOCYTE ACTIVATION; ANIMAL; DRUG COMBINATION; DRUG EFFECT; FLOW CYTOMETRY; METABOLISM; METHODOLOGY; NONOBESE DIABETIC MOUSE; PANCREAS;

ANIMALS; DIABETES MELLITUS, TYPE 1; DRUG COMBINATIONS; FLOW CYTOMETRY; IMMUNOTHERAPY; INTERLEUKIN-2; MALE; MICE; MICE, INBRED NOD; PANCREAS; SIROLIMUS; T-LYMPHOCYTES, REGULATORY;

EID: 84887343555     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-0214     Document Type: Article

References (45)

1. Bach JF. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr Rev 1994;15:516-542
2. Sreenan S, Pick AJ, Levisetti M, Baldwin AC, Pugh W, Polonsky KS. Increased beta-cell proliferation and reduced mass before diabetes onset in the nonobese diabetic mouse. Diabetes 1999;48:989-996
3. Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 2010;464:1293-1300
4. Waldron-Lynch F, Herold KC. Immunomodulatory therapy to preserve pancreatic b-cell function in type 1 diabetes. Nat Rev Drug Discov 2011;10: 439-452
5. Atkinson MA, Leiter EH. The NOD mouse model of type 1 diabetes: as good as it gets? Nat Med 1999;5:601-604
6. Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 1994;91:123-127
7. Bach JF. Anti-CD3 antibodies for type 1 diabetes: beyond expectations. Lancet 2011;378:459-460
8. Tang Q, Adams JY, Penaranda C, et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 2008;28:687-697
9. Grinberg-Bleyer Y, Baeyens A, You S, et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med 2010;207:1871-1878
10. Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. Annu Rev Immunol 1996;14:483-510
11. Piemonti L, Maffi P, Monti L, et al. Beta cell function during rapamycin monotherapy in long-term type 1 diabetes. Diabetologia 2011;54:433-439
12. Monti P, Scirpoli M, Maffi P, et al. Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+CD25+FOXP3+ regulatory T-cells. Diabetes 2008;57:2341-2347
13. Rabinovitch A, Suarez-Pinzon WL, Shapiro AM, Rajotte RV, Power R. Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice. Diabetes 2002;51:638-645
14. Valle A, Jofra T, Stabilini A, Atkinson M, Roncarolo MG, Battaglia M. Ra-pamycin prevents and breaks the anti-CD3-induced tolerance in NOD mice. Diabetes 2009;58:875-881
15. Cassan C, Piaggio E, Zappulla JP, et al. Pertussis toxin reduces the number of splenic Foxp3+ regulatory T cells. J Immunol 2006;177:1552-1560
16. Grinberg-Bleyer Y, Saadoun D, Baeyens A, et al. Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs. J Clin Invest 2010;120:4558-4568
17. Krieg C, Létourneau S, Pantaleo G, Boyman O. Improved IL-2 immuno-therapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc Natl Acad Sci USA 2010;107:11906-11911
18. Fu W, Wojtkiewicz G, Weissleder R, Benoist C, Mathis D. Early window of diabetes determinism in NOD mice, dependent on the complement receptor CRIg, identified by noninvasive imaging. Nat Immunol 2012;13:361-368
19. Trudeau JD, Kelly-Smith C, Verchere CB, et al. Prediction of spontaneous autoimmune diabetes in NOD mice by quantification of autoreactive T cells in peripheral blood. J Clin Invest 2003;111:217-223
20. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005;105:4743-4748
21. Billiard F, Litvinova E, Saadoun D, et al. Regulatory and effector T cell activation levels are prime determinants of in vivo immune regulation. J Immunol 2006;177:2167-2174
22. van Belle TL, Coppieters KT, von Herrath MG. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev 2011;91:79-118
23. Jansen A, Homo-Delarche F, Hooijkaas H, Leenen PJ, Dardenne M, Drexhage HA. Immunohistochemical characterization of monocytes-mac-rophages and dendritic cells involved in the initiation of the insulitis and beta-cell destruction in NOD mice. Diabetes 1994;43:667-675
24. Hu C, Du W, Zhang X, Wong FS, Wen L. The role of Gr1+ cells after anti-CD20 treatment in type 1 diabetes in nonobese diabetic mice. J Immunol 2012;188:294-301
25. Yin B, Ma G, Yen CY, et al. Myeloid-derived suppressor cells prevent type 1 diabetes in murine models. J Immunol 2010;185:5828-5834
26. Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 2009;9:324-337
27. Battaglia M, Stabilini A, Draghici E, et al. Induction of tolerance in type 1 diabetes via both CD4+CD25+ T regulatory cells and T regulatory type 1 cells. Diabetes 2006;55:1571-1580
28. Delgoffe GM, Kole TP, Zheng Y, et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 2009;30: 832-844
29. Kuo CJ, Chung J, Fiorentino DF, Flanagan WM, Blenis J, Crabtree GR. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature 1992;358:70-73
30. Long SA, Rieck M, Sanda S, et al.; Diabetes TrialNet and the Immune Tolerance Network. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs b-cell function. Diabetes 2012;61:2340-2348
31. Beilke JN, Meagher CT, Hosiawa K, Champsaur M, Bluestone JA, Lanier LL. NK cells are not required for spontaneous autoimmune diabetes in NOD mice. PLoS One 2012;7:e36011
32. Gur C, Porgador A, Elboim M, et al. The activating receptor NKp46 is essential for the development of type 1 diabetes. Nat Immunol 2010;11: 121-128
33. Gur C, Enk J, Kassem SA, et al. Recognition and killing of human and murine pancreatic beta cells by the NK receptor NKp46. J Immunol 2011; 187:3096-3103
34. Schleinitz N, Vély F, Harlé JR, Vivier E. Natural killer cells in human autoimmune diseases. Immunology 2010;131:451-458
35. Li Z, Lim WK, Mahesh SP, Liu B, Nussenblatt RB. Cutting edge: in vivo blockade of human IL-2 receptor induces expansion of CD56(bright) regulatory NK cells in patients with active uveitis. J Immunol 2005;174:5187-5191
36. Bielekova B, Catalfamo M, Reichert-Scrivner S, et al. Regulatory CD56 (bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 2006;103:5941-5946
37. Koreth J, Matsuoka K, Kim HT, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011;365:2055-2066
38. Saadoun D, Rosenzwajg M, Joly F, et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 2011;365: 2067-2077
39. Feuerer M, Shen Y, Littman DR, Benoist C, Mathis D. How punctual ablation of regulatory T cells unleashes an autoimmune lesion within the pancreatic islets. Immunity 2009;31:654-664
40. Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008;19:1411-1418
41. Houde VP, Brûlé S, Festuccia WT, et al. Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes 2010;59:1338-1348
42. Lamming DW, Ye L, Katajisto P, et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 2012;335:1638-1643
43. Cunningham JT, Rodgers JT, Arlow DH, Vazquez F, Mootha VK, Puigserver P. mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature 2007;450:736-740
44. Baeder WL, Sredy J, Sehgal SN, Chang JY, Adams LM. Rapamycin prevents the onset of insulin-dependent diabetes mellitus (IDDM) in NOD mice. Clin Exp Immunol 1992;89:174-178
45. Shin HJ, Baker J, Leveson-Gower DB, Smith AT, Sega EI, Negrin RS. Ra-pamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells. Blood 2011;118:2342-2350